Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States.

Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, Barlow WE, Burnside ES, Conant EF, Hampton JM, Huang H, Kerlikowske K, Lee SJ, Miglioretti DL, Sprague BL, Tosteson ANA, Yaffe M, Stout NK.

J Natl Cancer Inst. 2019 Sep 10. pii: djz184. doi: 10.1093/jnci/djz184. [Epub ahead of print]

PMID:
31503283
2.

Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study.

Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, Gralow JR, Hortobagyi GN, Smerage JB, Barlow WE, Hayes DF.

Clin Cancer Res. 2019 Jul 29. doi: 10.1158/1078-0432.CCR-19-0208. [Epub ahead of print]

PMID:
31358544
3.

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims.

Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM.

Arch Osteoporos. 2019 Jul 28;14(1):83. doi: 10.1007/s11657-019-0629-7.

PMID:
31352608
4.

Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.

Barlow WE, Beaber EF, Geller BM, Kamineni A, Zheng Y, Haas JS, Chao CR, Rutter CM, Zauber AG, Sprague BL, Halm EA, Weaver DL, Chubak J, Doria-Rose VP, Kobrin S, Onega T, Quinn VP, Schapira MM, Tosteson ANA, Corley DA, Skinner CS, Schnall MD, Armstrong K, Wheeler CM, Silverberg MJ, Balasubramanian BA, Doubeni CA, McLerran D, Tiro JA.

J Natl Cancer Inst. 2019 Jul 11. pii: djz137. doi: 10.1093/jnci/djz137. [Epub ahead of print]

PMID:
31292633
5.

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial.

Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh ZA, Hayes DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L.

J Immunother Cancer. 2019 Apr 10;7(1):88. doi: 10.1186/s40425-019-0563-7.

6.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S.

Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6.

PMID:
30928413
7.

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN.

N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714. Erratum in: N Engl J Med. 2019 Jun 6;380(23):2282.

PMID:
30917258
8.

Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density.

Conant EF, Barlow WE, Herschorn SD, Weaver DL, Beaber EF, Tosteson ANA, Haas JS, Lowry KP, Stout NK, Trentham-Dietz A, diFlorio-Alexander RM, Li CI, Schnall MD, Onega T, Sprague BL; Population-based Research Optimizing Screening Through Personalized Regimen (PROSPR) Consortium.

JAMA Oncol. 2019 May 1;5(5):635-642. doi: 10.1001/jamaoncol.2018.7078.

PMID:
30816931
9.

Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50-74 Years in a Screening Population.

Beaber EF, Sprague BL, Tosteson ANA, Haas JS, Onega T, Schapira MM, McCarthy AM, Li CI, Herschorn SD, Lehman CD, Wernli KJ, Barlow WE.

J Womens Health (Larchmt). 2019 Aug;28(8):1051-1059. doi: 10.1089/jwh.2018.6997. Epub 2018 Nov 27.

PMID:
30481098
10.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

11.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
12.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Aug;55:117-122. doi: 10.1016/j.canep.2018.06.005. Epub 2018 Jun 21.

13.

Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results.

McCarthy AM, Barlow WE, Conant EF, Haas JS, Li CI, Sprague BL, Armstrong K; PROSPR Consortium.

JAMA Oncol. 2018 Jul 1;4(7):998-1001. doi: 10.1001/jamaoncol.2018.0352. No abstract available.

14.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L.

Mol Cancer Ther. 2018 Jun;17(6):1324-1331. doi: 10.1158/1535-7163.MCT-17-1005. Epub 2018 Mar 27.

15.

Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.

Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, Unger JM.

J Clin Oncol. 2018 Sep 10;36(26):2710-2717. doi: 10.1200/JCO.2017.77.4414. Epub 2018 Mar 27.

16.

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.

Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr.

J Natl Cancer Inst. 2018 Nov 1;110(11):1208-1215. doi: 10.1093/jnci/djy035.

17.

Communication Practices of Mammography Facilities and Timely Follow-up of a Screening Mammogram with a BI-RADS 0 Assessment.

Schapira MM, Barlow WE, Conant EF, Sprague BL, Tosteson ANA, Haas JS, Onega T, Beaber EF, Goodrich M, McCarthy AM, Herschorn SD, Skinner CS, Harrington TO, Geller B.

Acad Radiol. 2018 Sep;25(9):1118-1127. doi: 10.1016/j.acra.2017.12.028. Epub 2018 Feb 9.

18.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.

Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.

19.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

20.

History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials.

Hershman DL, Till C, Wright JD, Ramsey S, Barlow WE, Unger JM.

JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00040.

21.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.

PMID:
29035643
22.

Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Res. 2017 Nov 1;77(21):6033-6041. doi: 10.1158/0008-5472.CAN-17-0687. Epub 2017 Sep 21.

23.

Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer.

Janes H, Brown MD, Crager MR, Miller DP, Barlow WE.

Contemp Clin Trials. 2017 Dec;63:30-39. doi: 10.1016/j.cct.2017.08.004. Epub 2017 Aug 14.

24.

Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population.

Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1603-1610. doi: 10.1158/1055-9965.EPI-17-0346. Epub 2017 Aug 14.

25.
26.

Evidence for Detection Bias by Medication Use in a Cohort Study of Breast Cancer Survivors.

Wirtz HS, Calip GS, Buist DSM, Gralow JR, Barlow WE, Gray S, Boudreau DM.

Am J Epidemiol. 2017 Apr 15;185(8):661-672. doi: 10.1093/aje/kww242.

27.

Primary Care Providers' Beliefs and Recommendations and Use of Screening Mammography by their Patients.

Haas JS, Barlow WE, Schapira MM, MacLean CD, Klabunde CN, Sprague BL, Beaber EF, Chen JS, Bitton A, Onega T, Harris K, Tosteson ANA; PROSPR (Population-based Research Optimizing Screening through Personalized Regimens) consortium.

J Gen Intern Med. 2017 Apr;32(4):449-457. doi: 10.1007/s11606-016-3973-y. Epub 2017 Jan 9.

28.

Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.

Beaber EF, Tosteson AN, Haas JS, Onega T, Sprague BL, Weaver DL, McCarthy AM, Doubeni CA, Quinn VP, Skinner CS, Zauber AG, Barlow WE.

Breast Cancer Res Treat. 2016 Nov;160(2):323-331. Epub 2016 Sep 24.

29.

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Unger JM, Till C, Thompson IM Jr, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, Hershman DL.

J Natl Cancer Inst. 2016 Aug 26;108(12). pii: djw168. doi: 10.1093/jnci/djw168. Print 2016 Dec.

30.

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30.

31.

Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study.

Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF, Herschorn SD, Lehman CD, Tosteson AN, Lacson R, Schnall MD, Kontos D, Haas JS, Weaver DL, Barlow WE; PROSPR Consortium.

Ann Intern Med. 2016 Oct 4;165(7):457-464. doi: 10.7326/M15-2934. Epub 2016 Jul 19.

32.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Nahleh ZA, Barlow WE, Hayes DF, Schott AF, Gralow JR, Sikov WM, Perez EA, Chennuru S, Mirshahidi HR, Corso SW, Lew DL, Pusztai L, Livingston RB, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;158(3):485-95. doi: 10.1007/s10549-016-3889-6. Epub 2016 Jul 8.

33.

Measuring the Real Clinical Impact of Randomized Clinical Trials in Oncology-Reply: Beyond Citation Counts.

Unger JM, Barlow WE, Hershman DL.

JAMA Oncol. 2016 Nov 1;2(11):1511. doi: 10.1001/jamaoncol.2016.1772. No abstract available.

PMID:
27355398
34.

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, Minasian LM, Unger J.

J Clin Oncol. 2016 Sep 1;34(25):3014-22. doi: 10.1200/JCO.2015.66.2346. Epub 2016 Jun 20.

35.

Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity.

McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde CN, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA; PROSPR consortium.

Am J Prev Med. 2016 Oct;51(4):507-12. doi: 10.1016/j.amepre.2016.03.017. Epub 2016 Apr 28.

36.

The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL.

JAMA Oncol. 2016 Jul 1;2(7):875-81. doi: 10.1001/jamaoncol.2015.6487.

37.

Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium.

Conant EF, Beaber EF, Sprague BL, Herschorn SD, Weaver DL, Onega T, Tosteson AN, McCarthy AM, Poplack SP, Haas JS, Armstrong K, Schnall MD, Barlow WE.

Breast Cancer Res Treat. 2016 Feb;156(1):109-16. doi: 10.1007/s10549-016-3695-1. Epub 2016 Mar 1.

38.

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM.

Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8.

39.

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M.

JAMA Oncol. 2016 Apr;2(4):453-61. doi: 10.1001/jamaoncol.2015.4655.

40.

Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium.

Tosteson AN, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, Barlow WE, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, Kamineni A, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium.

J Gen Intern Med. 2016 Apr;31(4):372-9. doi: 10.1007/s11606-015-3552-7.

41.

Reply to F.-C. Bidard et al.

Smerage JB, Barlow WE, Hortobagyi GN, Hayes DF.

J Clin Oncol. 2015 May 10;33(14):1623. doi: 10.1200/JCO.2014.60.5519. Epub 2015 Apr 13. No abstract available.

PMID:
25870090
42.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators.

N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204.

43.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.

J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.

44.

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN.

J Clin Oncol. 2015 Jan 1;33(1):58-64. doi: 10.1200/JCO.2014.56.3296. Epub 2014 Nov 24.

45.

Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.

Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, Li CI.

Cancer Res. 2014 Aug 1;74(15):4078-89. doi: 10.1158/0008-5472.CAN-13-3400.

46.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF.

J Clin Oncol. 2014 Nov 1;32(31):3483-9. doi: 10.1200/JCO.2014.56.2561. Epub 2014 Jun 2.

47.

Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level.

Onega T, Beaber EF, Sprague BL, Barlow WE, Haas JS, Tosteson AN, D Schnall M, Armstrong K, Schapira MM, Geller B, Weaver DL, Conant EF.

Cancer. 2014 Oct 1;120(19):2955-64. doi: 10.1002/cncr.28771. Epub 2014 May 15. Review.

48.

Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy.

Pocobelli G, Newcomb PA, Li CI, Cook LS, Barlow WE, Weiss NS.

Breast Cancer Res Treat. 2014 Jun;145(2):439-47. doi: 10.1007/s10549-014-2911-0. Epub 2014 Mar 27. Erratum in: Breast Cancer Res Treat. 2014 Jun;145(2):449.

49.

Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):755-64. doi: 10.1158/1055-9965.EPI-13-0944. Epub 2014 Mar 14.

50.

Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL.

J Natl Cancer Inst. 2014 Mar;106(3):dju002. doi: 10.1093/jnci/dju002. Epub 2014 Mar 13.

Supplemental Content

Loading ...
Support Center